发明名称 PYRROLOPYRIDINE INHIBITORS OF KINASES
摘要 The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts,;;wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.
申请公布号 US2014357616(A1) 申请公布日期 2014.12.04
申请号 US201414444540 申请日期 2014.07.28
申请人 AbbVie Inc. 发明人 Penning Thomas D.;Woods Keith W.;Lai Chunqiu;Florjancic Alan S.;Tong Yunsong
分类号 C07D471/04 主分类号 C07D471/04
代理机构 代理人
主权项 1. A compound having formula (I) wherein R1a, R1b and R1c are independently hydrogen, hydroxy, nitro, halogen, cyano, trifluoromethyl, trifluoromethoxy, C1-4-alkyl, —ORa, —NRbRc; —C(O)ORa, —C(O)NRbRc, —NRbC(O)Rc, —NHC(O)NHRb, or —NHSO2Ra; X is N; R2 is hydrogen or C1-4-alkyl; Y is NR3R4, NR6C(O)R2, NR6SO2R2, aryl, or heterocyclyl, wherein the aryl and heterocyclyl are optionally substituted with one or more R5; R3 is hydrogen, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C3-8-cycloalkyl, C3-8-cycloalkyl-(C1-8-alkyl)-, heterocycloalkyl, heterocycloalkyl-(C1-8-alkyl)-, aryl, aryl-(C1-8-alkyl)-, heteroaryl-, or heteroaryl-(C1-8-alkyl), wherein (a) the R3C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl substituents, alone or as part of another group, are optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, —ORa, —C(O)Ra, —C(O)ORa, —OC(O)Ra, —NRbRc, —NRbC(O)Ra, —NHC(O)NHRb, —C(O)NRbRc, —NHSO2Ra, —SO2NRbNRc, and aryl; and (b) the R3C3-8-cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, alone or as part of another group, are optionally substituted with one or more R5; R4 is hydrogen or C1-8-alkyl; wherein the C1-8-alkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, —ORa, —C(O)Ra, —C(O)ORa, —OC(O)Ra, —NRbRc, —NRbC(O)Ra, —NHC(O)NHRb, —C(O)NRbRc, —NHSO2Ra, and —SO2NRbNRc; R5 is selected from the group consisting of C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, halogen, cyano, nitro, —ORd, —C(O)Rd, —C(O)ORd, —OC(O)Rd, —NReRf, —NReC(O)Rd, —NHC(O)NHRe, —NHSO2Re, —C(O)NReRf, —SRd, —S(O)Rd, —SO2Rd, —SO2NReNRf, −B(OH)2, —CF3, —CF2CF3, —OCF3, and —OCF2CF3 wherein (a) the R5C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, substituents are optionally substituted with one or more substituents selected from the group consisting of aryl, heterocyclyl, C3-8-cycloalkyl, halogen, cyano, nitro, —ORd, C(O)Rd, C(O)ORd, —OC(O)Rd, —NReRf, —NReC(O)Rd, —NHC(O)NHRe, —C(O)NReRf; and wherein (b) the R5 aryl or heterocyclyl substituents are optionally substituted with one or more substituents independently selected from the group consisting of C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, halogen, cyano, nitro, —ORg, —C(O)Rg, —C(O)ORg, —OC(O)Rg, —NRhRi, —NRhC(O)Rg, —NHC(O)NHRh, —NHSO2Rg, —C(O)NRhRi, —SRg, —S(O)Rg, —SO2Rg, —SO2NRhNRi, —CF3, —CF2CF3, —OCF3, and —OCF2CF3; R6 is hydrogen or C1-8-alkyl; R7 is C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C3-8-cycloalkyl, C3-8-cycloalkyl-(C1-8-alkyl)-, heterocycloalkyl, heterocycloalkyl-(C1-8-alkyl)-, aryl, aryl-(C1-8-alkyl)-, heteroaryl-, or heteroaryl-(C1-8-alkyl)-, wherein (a) the R7C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl substituents, alone or as part of another group, are optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, —ORa, —C(O)Ra, —C(O)ORa, —OC(O)Ra, —NRbRc, —NRbC(O)Ra, —NHC(O)NHRh, —C(O)NRbRc, —NHSO2Ra, —SO2NR6NRe, and aryl; and (b) the R7C3-8-cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, alone or as part of another group, are optionally substituted with one or more R5; Ra, at each occurrence, is selected from the group consisting of hydrogen, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, and C3-8-cycloalkyl, wherein the C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, and C3-8-cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of C1-8-alkyl, aryl, heterocyclyl, C3-8-cycloalkyl, halogen, cyano, hydroxy, C1-8-alkoxy, —NH2, —NH(C1-8-alkyl), —O (C1-8-alkyl)NH2, and —N(C1-8-alkyl)2; Rb and Rc, at each occurrence, are independently selected from the group consisting of hydrogen, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, and C3-8-cycloalkyl, and optionally, Rb and Rc can be joined together to form a 4-7 membered heterocycloalkyl ring, wherein the C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, C3-8-cycloalkyl, and 4-7 membered heterocycloalkyl ring are optionally substituted with one or more substituents independently selected from the group consisting of C1-8-alkyl, aryl, heterocyclyl, C3-8-cycloalkyl, halogen, cyano, hydroxy, C1-8-alkoxy, —NH2, —NH(C1-8-alkyl), and —N(C1-8-alkyl)2; Rd, at each occurrence, is selected from the group consisting of hydrogen, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, and C3-8-cycloalkyl, wherein the C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, and C3-8-cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of C1-8-alkyl, aryl, aryl-(C1-8-alkyl)-, heterocyclyl, C3-8-cycloalkyl, halogen, cyano, oxo, hydroxy, C1-8-alkoxy, —NH2, —NH(C1-8-alkyl), and —N(C1-8-alkyl)2; wherein the aryl, aryl-(C1-8-alkyl), heterocyclyl, and C3-8-cycloalkyl, alone or as part of another group, are optionally substituted with one or more substituents independently selected from the group consisting of C1-8-alkyl, aryl, heterocyclyl, C3-8-cycloalkyl, halogen, cyano, hydroxy, C1-8-alkoxy, —NH2, —NH(C1-8-alkyl), and —N(C1-8-alkyl)2; Re and Rf, at each occurrence, are independently selected from the group consisting of hydrogen, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, and C3-8-cycloalkyl, and optionally, Re and Rf can be joined together to form a 4-7 membered heterocycloalkyl ring, wherein the C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, C3-8-cycloalkyl, and 4-7 membered heterocycloalkyl ring are optionally substituted with one or more substituents independently selected from the group consisting of C1-8-alkyl, aryl, heterocyclyl, C3-8-cycloalkyl, halogen, cyano, hydroxy, C1-8-alkoxy, —NH2, —NH(C1-8-alkyl), and —N(C1-8-alkyl)2; Rg, at each occurrence, is selected from the group consisting of hydrogen, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, and C3-8-cycloalkyl, wherein the C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, and C3-8-cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of C1-8-alkyl, aryl, heterocyclyl, C3-8-cycloalkyl, halogen, cyano, hydroxy, C1-8-alkoxy, —NH2, —NH(C1-8-alkyl), and —N(C1-8-alkyl)2; Rh and Ri, at each occurrence, are independently selected from the group consisting of hydrogen, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, and C3-8-cycloalkyl, and optionally, Rh and Ri can be joined together to form a 4-7 membered heterocycloalkyl ring, wherein the C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, aryl, heterocyclyl, C3-8-cycloalkyl, and 4-7 membered heterocycloalkyl ring are optionally substituted with one or more substituents independently selected from the group consisting of C1-8-alkyl, aryl, heterocyclyl, C3-8-cycloalkyl, halogen, cyano, hydroxy, C1-8-alkoxy, —NH2, —NH(C1-8-alkyl), and —N(C1-8-alkyl)2; or a pharmaceutically acceptable salt thereof.
地址 North Chicago IL US